Author pages are created from data sourced from our academic publisher partnerships and public sources.
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
- M. Guix, N. M. Granja, +15 authors C. Arteaga
- Journal of clinical oncology : official journal…
- 20 February 2008
PURPOSE To administer the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to patients with operable untreated breast cancer during the immediate preoperative period and to… Expand